OCT 07, 2019 2:05 PM PDT

It's not all bad: cancer and aging

Research published recently in the journal Aging Cell highlights the complexities of the interactions that occur during the aging process from the angle of how it relates to cancer. Surprisingly, the findings report that although aging is one of the greatest risks for cancer, the natural process of senescence that cells go through as they age may actually deter cancer cells’ development.

Senescence refers to the progression of cells’ lives when they become dormant and stop growing, dividing, and renewing. It has long been thought that aging senescent cells have a higher probability of turning cancerous because of an accumulation of multiple mutations in cancer causing-genes. Yet, by definition itself, senescence is the opposite process of cancer: the cease of dividing cells versus the uncontrollable division and growth of cells.

"You have these two opposite forces: mutations driving cancer and tissue degeneration hindering it,” explains lead author Professor João Pedro de Magalhães from the University of Liverpool in the UK.

understand more about the role that senescence plays in cancer, the research team analyzed the genes that have been observed in the cancer progression of nine different human tissues. They wanted to determine their state of activity/non-activity, in order to see how the cells were behaving under certain age conditions.

New research exposes how senescence hinders cancer progression. Photo: Pixabay

What they observed was that for all the tissues they analyzed except those from the thyroid and the uterus, aging and cancer gene activity patterns changed in opposite directions – which is to say that some aging genes were more active while some cancer genes were less active. Thyroid and uterine tissues were the exceptions to this trend, with both aging genes and cancer genes changing in the same direction.

These findings dig deeper into the complexities of aging and cancer and could potentially explain why although older people are at a higher risk of developing cancer, the incidence of cancer also levels off toward the end of life. The researchers say that though this is a good start, much more investigation will be needed in order to fully understand all the inner workings between these interactions.

Sources: Aging CellMedical News Today

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 14, 2020
Cancer
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
SEP 14, 2020
MiR-107 and Its Role in Radiosensitivity in Prostate Cancer
It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
OCT 26, 2020
Cancer
Investigating the Receptor Protein FPR1 in Brain Cancer
OCT 26, 2020
Investigating the Receptor Protein FPR1 in Brain Cancer
Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – us ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
Loading Comments...